Does a p53 Wild-type Immunophenotype Exclude a Diagnosis of Endometrial Serous Carcinoma?

Oluwole Fadare, Andres A. Roma, Vinita Parkash, Wenxin - Zheng, Vighnesh Walavalkar

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

An aberrant p53 immunophenotype may be identified in several histotypes of endometrial carcinoma, and is accordingly recognized to lack diagnostic specificity in and of itself. However, based on the high frequency with which p53 aberrations have historically been identified in endometrial serous carcinoma, a mutation- type immunophenotype is considered to be highly sensitive for the histotype. Using an illustrative case study and a review of the literature, we explore a relatively routine diagnostic question: whether the negative predictive value of a wild-type p53 immunophenotype for serous carcinoma is absolute, that is, whether a p53-wild type immunophenotype is absolutely incompatible with a diagnosis of serous carcinoma. The case is an advanced stage endometrial carcinoma that was reproducibly classified by pathologists from 3 institutions as serous carcinoma based on its morphologic features. By immunohistochemistry, the tumor was p53-wild type (DO-7 clone), diffusely positive for p16 (block positivity), and showed retained expression of PTEN, MSH2, MSH6, MLH1, and PMS2. Next generation sequencing showed that there indeed was an underlying mutation in TP53 (D393fs∗78, R213∗). The tumor was microsatellite stable, had a low mutational burden (4 mutations per MB), and displayed no mutations in the exonuclease domain of DNA polymerase epsilon (POLE) gene. Other genomic alterations included RB1 mutation (R46fs∗19), amplifications in MYST3 and CRKL, and ARID1A deletion (splice site 5125- 94-5138del108). A review of the recent literature identified 5 studies in which a total of 259 cases of serous carcinoma were whole-exome sequenced. The average TP53 mutational rate in endometrial serous carcinoma was only 75% (range, 60 to 88). A total of 12 (33%) of 36 immunohistochemical studies reported a p53-aberrant rate of <80% in endometrial serous carcinoma. We discuss in detail several potential explanations that may underlie the scenario of serous carcinoma-like morphology combined with p53-wild-type immunophenotype, including analytic limitations, a nonserous histotype displaying morphologic mimicry of serous carcinoma, and true biological phenomena (including the possibility of a TP53-independent pathway of endometrial serous carcinogenesis). Ultimately, our central thematic question is provisionally answered in the negative. At present, the available data would not support a categorical conclusion that a p53 alteration is a necessary and obligate component in the genesis and/or diagnosis of endometrial serous carcinoma. On the basis of their collective experience, the authors proffer some recommendations on the use of p53 immunohistochemistry in the histotyping of endometrial carcinomas.

Original languageEnglish (US)
Pages (from-to)61-70
Number of pages10
JournalAdvances in Anatomic Pathology
Volume25
Issue number1
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Endometrial Neoplasms
Carcinoma
Mutation
DNA Polymerase II
Immunohistochemistry
Exome
Biological Phenomena
Exonucleases
Microsatellite Repeats
Neoplasms
Carcinogenesis
Clone Cells
Genes

Keywords

  • Endometrial serous carcinoma
  • Immunohistochemistry
  • P53
  • Wild-type

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine

Cite this

Does a p53 Wild-type Immunophenotype Exclude a Diagnosis of Endometrial Serous Carcinoma? / Fadare, Oluwole; Roma, Andres A.; Parkash, Vinita; Zheng, Wenxin -; Walavalkar, Vighnesh.

In: Advances in Anatomic Pathology, Vol. 25, No. 1, 01.01.2018, p. 61-70.

Research output: Contribution to journalReview article

Fadare, Oluwole ; Roma, Andres A. ; Parkash, Vinita ; Zheng, Wenxin - ; Walavalkar, Vighnesh. / Does a p53 Wild-type Immunophenotype Exclude a Diagnosis of Endometrial Serous Carcinoma?. In: Advances in Anatomic Pathology. 2018 ; Vol. 25, No. 1. pp. 61-70.
@article{f3192f7603e64f8c91b250b3873a7488,
title = "Does a p53 Wild-type Immunophenotype Exclude a Diagnosis of Endometrial Serous Carcinoma?",
abstract = "An aberrant p53 immunophenotype may be identified in several histotypes of endometrial carcinoma, and is accordingly recognized to lack diagnostic specificity in and of itself. However, based on the high frequency with which p53 aberrations have historically been identified in endometrial serous carcinoma, a mutation- type immunophenotype is considered to be highly sensitive for the histotype. Using an illustrative case study and a review of the literature, we explore a relatively routine diagnostic question: whether the negative predictive value of a wild-type p53 immunophenotype for serous carcinoma is absolute, that is, whether a p53-wild type immunophenotype is absolutely incompatible with a diagnosis of serous carcinoma. The case is an advanced stage endometrial carcinoma that was reproducibly classified by pathologists from 3 institutions as serous carcinoma based on its morphologic features. By immunohistochemistry, the tumor was p53-wild type (DO-7 clone), diffusely positive for p16 (block positivity), and showed retained expression of PTEN, MSH2, MSH6, MLH1, and PMS2. Next generation sequencing showed that there indeed was an underlying mutation in TP53 (D393fs∗78, R213∗). The tumor was microsatellite stable, had a low mutational burden (4 mutations per MB), and displayed no mutations in the exonuclease domain of DNA polymerase epsilon (POLE) gene. Other genomic alterations included RB1 mutation (R46fs∗19), amplifications in MYST3 and CRKL, and ARID1A deletion (splice site 5125- 94-5138del108). A review of the recent literature identified 5 studies in which a total of 259 cases of serous carcinoma were whole-exome sequenced. The average TP53 mutational rate in endometrial serous carcinoma was only 75{\%} (range, 60 to 88). A total of 12 (33{\%}) of 36 immunohistochemical studies reported a p53-aberrant rate of <80{\%} in endometrial serous carcinoma. We discuss in detail several potential explanations that may underlie the scenario of serous carcinoma-like morphology combined with p53-wild-type immunophenotype, including analytic limitations, a nonserous histotype displaying morphologic mimicry of serous carcinoma, and true biological phenomena (including the possibility of a TP53-independent pathway of endometrial serous carcinogenesis). Ultimately, our central thematic question is provisionally answered in the negative. At present, the available data would not support a categorical conclusion that a p53 alteration is a necessary and obligate component in the genesis and/or diagnosis of endometrial serous carcinoma. On the basis of their collective experience, the authors proffer some recommendations on the use of p53 immunohistochemistry in the histotyping of endometrial carcinomas.",
keywords = "Endometrial serous carcinoma, Immunohistochemistry, P53, Wild-type",
author = "Oluwole Fadare and Roma, {Andres A.} and Vinita Parkash and Zheng, {Wenxin -} and Vighnesh Walavalkar",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/PAP.0000000000000171",
language = "English (US)",
volume = "25",
pages = "61--70",
journal = "Advances in Anatomic Pathology",
issn = "1072-4109",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Does a p53 Wild-type Immunophenotype Exclude a Diagnosis of Endometrial Serous Carcinoma?

AU - Fadare, Oluwole

AU - Roma, Andres A.

AU - Parkash, Vinita

AU - Zheng, Wenxin -

AU - Walavalkar, Vighnesh

PY - 2018/1/1

Y1 - 2018/1/1

N2 - An aberrant p53 immunophenotype may be identified in several histotypes of endometrial carcinoma, and is accordingly recognized to lack diagnostic specificity in and of itself. However, based on the high frequency with which p53 aberrations have historically been identified in endometrial serous carcinoma, a mutation- type immunophenotype is considered to be highly sensitive for the histotype. Using an illustrative case study and a review of the literature, we explore a relatively routine diagnostic question: whether the negative predictive value of a wild-type p53 immunophenotype for serous carcinoma is absolute, that is, whether a p53-wild type immunophenotype is absolutely incompatible with a diagnosis of serous carcinoma. The case is an advanced stage endometrial carcinoma that was reproducibly classified by pathologists from 3 institutions as serous carcinoma based on its morphologic features. By immunohistochemistry, the tumor was p53-wild type (DO-7 clone), diffusely positive for p16 (block positivity), and showed retained expression of PTEN, MSH2, MSH6, MLH1, and PMS2. Next generation sequencing showed that there indeed was an underlying mutation in TP53 (D393fs∗78, R213∗). The tumor was microsatellite stable, had a low mutational burden (4 mutations per MB), and displayed no mutations in the exonuclease domain of DNA polymerase epsilon (POLE) gene. Other genomic alterations included RB1 mutation (R46fs∗19), amplifications in MYST3 and CRKL, and ARID1A deletion (splice site 5125- 94-5138del108). A review of the recent literature identified 5 studies in which a total of 259 cases of serous carcinoma were whole-exome sequenced. The average TP53 mutational rate in endometrial serous carcinoma was only 75% (range, 60 to 88). A total of 12 (33%) of 36 immunohistochemical studies reported a p53-aberrant rate of <80% in endometrial serous carcinoma. We discuss in detail several potential explanations that may underlie the scenario of serous carcinoma-like morphology combined with p53-wild-type immunophenotype, including analytic limitations, a nonserous histotype displaying morphologic mimicry of serous carcinoma, and true biological phenomena (including the possibility of a TP53-independent pathway of endometrial serous carcinogenesis). Ultimately, our central thematic question is provisionally answered in the negative. At present, the available data would not support a categorical conclusion that a p53 alteration is a necessary and obligate component in the genesis and/or diagnosis of endometrial serous carcinoma. On the basis of their collective experience, the authors proffer some recommendations on the use of p53 immunohistochemistry in the histotyping of endometrial carcinomas.

AB - An aberrant p53 immunophenotype may be identified in several histotypes of endometrial carcinoma, and is accordingly recognized to lack diagnostic specificity in and of itself. However, based on the high frequency with which p53 aberrations have historically been identified in endometrial serous carcinoma, a mutation- type immunophenotype is considered to be highly sensitive for the histotype. Using an illustrative case study and a review of the literature, we explore a relatively routine diagnostic question: whether the negative predictive value of a wild-type p53 immunophenotype for serous carcinoma is absolute, that is, whether a p53-wild type immunophenotype is absolutely incompatible with a diagnosis of serous carcinoma. The case is an advanced stage endometrial carcinoma that was reproducibly classified by pathologists from 3 institutions as serous carcinoma based on its morphologic features. By immunohistochemistry, the tumor was p53-wild type (DO-7 clone), diffusely positive for p16 (block positivity), and showed retained expression of PTEN, MSH2, MSH6, MLH1, and PMS2. Next generation sequencing showed that there indeed was an underlying mutation in TP53 (D393fs∗78, R213∗). The tumor was microsatellite stable, had a low mutational burden (4 mutations per MB), and displayed no mutations in the exonuclease domain of DNA polymerase epsilon (POLE) gene. Other genomic alterations included RB1 mutation (R46fs∗19), amplifications in MYST3 and CRKL, and ARID1A deletion (splice site 5125- 94-5138del108). A review of the recent literature identified 5 studies in which a total of 259 cases of serous carcinoma were whole-exome sequenced. The average TP53 mutational rate in endometrial serous carcinoma was only 75% (range, 60 to 88). A total of 12 (33%) of 36 immunohistochemical studies reported a p53-aberrant rate of <80% in endometrial serous carcinoma. We discuss in detail several potential explanations that may underlie the scenario of serous carcinoma-like morphology combined with p53-wild-type immunophenotype, including analytic limitations, a nonserous histotype displaying morphologic mimicry of serous carcinoma, and true biological phenomena (including the possibility of a TP53-independent pathway of endometrial serous carcinogenesis). Ultimately, our central thematic question is provisionally answered in the negative. At present, the available data would not support a categorical conclusion that a p53 alteration is a necessary and obligate component in the genesis and/or diagnosis of endometrial serous carcinoma. On the basis of their collective experience, the authors proffer some recommendations on the use of p53 immunohistochemistry in the histotyping of endometrial carcinomas.

KW - Endometrial serous carcinoma

KW - Immunohistochemistry

KW - P53

KW - Wild-type

UR - http://www.scopus.com/inward/record.url?scp=85038230738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038230738&partnerID=8YFLogxK

U2 - 10.1097/PAP.0000000000000171

DO - 10.1097/PAP.0000000000000171

M3 - Review article

VL - 25

SP - 61

EP - 70

JO - Advances in Anatomic Pathology

JF - Advances in Anatomic Pathology

SN - 1072-4109

IS - 1

ER -